These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36507223)

  • 1. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination.
    Geers D; Sablerolles RSG; van Baarle D; Kootstra NA; Rietdijk WJR; Schmitz KS; Gommers L; Bogers S; Nieuwkoop NJ; van Dijk LLA; van Haren E; Lafeber M; Dalm VASH; Goorhuis A; Postma DF; Visser LG; Huckriede ALW; Sette A; Grifoni A; de Swart RL; Koopmans MPG; van der Kuy PHM; GeurtsvanKessel CH; de Vries RD;
    iScience; 2023 Jan; 26(1):105753. PubMed ID: 36507223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
    Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
    Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
    Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
    Moyo-Gwete T; Richardson SI; Keeton R; Hermanus T; Spencer H; Manamela NP; Ayres F; Makhado Z; Motlou T; Tincho MB; Benede N; Ngomti A; Baguma R; Chauke MV; Mennen M; Adriaanse M; Skelem S; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Riou C; Burgers WA; Moore PL
    PLoS Pathog; 2023 Nov; 19(11):e1011772. PubMed ID: 37943890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homologous and Heterologous Covid-19 Booster Vaccinations.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
    Moyo-Gwete T; Richardson SI; Keeton R; Hermanus T; Spencer H; Manamela NP; Ayres F; Makhado Z; Motlou T; Tincho MB; Benede N; Ngomti A; Baguma R; Chauke MV; Mennen M; Adriaanse M; Skelem S; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Riou C; Burgers WA; Moore PL
    medRxiv; 2023 Mar; ():. PubMed ID: 36993404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
    Riou C; Bhiman JN; Ganga Y; Sawry S; Ayres F; Baguma R; Balla SR; Benede N; Bernstein M; Besethi AS; Cele S; Crowther C; Dhar M; Geyer S; Gill K; Grifoni A; Hermanus T; Kaldine H; Keeton RS; Kgagudi P; Khan K; Lazarus E; Le Roux J; Lustig G; Madzivhandila M; Magugu SFJ; Makhado Z; Manamela NP; Mkhize Q; Mosala P; Motlou TP; Mutavhatsindi H; Mzindle NB; Nana A; Nesamari R; Ngomti A; Nkayi AA; Nkosi TP; Omondi MA; Panchia R; Patel F; Sette A; Singh U; van Graan S; Venter EM; Walters A; Moyo-Gwete T; Richardson SI; Garrett N; Rees H; Bekker LG; Gray G; Burgers WA; Sigal A; Moore PL; Fairlie L
    PLOS Glob Public Health; 2024; 4(4):e0002703. PubMed ID: 38603677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
    Riou C; Bhiman JN; Ganga Y; Sawry S; Ayres F; Baguma R; Balla SR; Benede N; Bernstein M; Besethi AS; Cele S; Crowther C; Dhar M; Geyer S; Gill K; Grifoni A; Hermanus T; Kaldine H; Keeton RS; Kgagudi P; Khan K; Lazarus E; Roux JL; Lustig G; Madzivhandila M; Magugu SF; Makhado Z; Manamela NP; Mkhize Q; Mosala P; Motlou TP; Mutavhatsindi H; Mzindle NB; Nana A; Nesamari R; Ngomti A; Nkayi AA; Nkosi TP; Omondi MA; Panchia R; Patel F; Sette A; Singh U; van Graan S; Venter EM; Walters A; Moyo-Gwete T; Richardson SI; Garrett N; Rees H; Bekker LG; Gray G; Burgers WA; Sigal A; Moore PL; Fairlie L
    medRxiv; 2023 Nov; ():. PubMed ID: 38045321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
    Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
    Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
    Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
    BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.
    Tan CS; Collier AY; Yu J; Liu J; Chandrashekar A; McMahan K; Jacob-Dolan C; He X; Roy V; Hauser BM; Munt JE; Mallory ML; Mattocks M; Powers JM; Meganck RM; Rowe M; Hemond R; Bondzie EA; Jaegle KH; Baric RS; Schmidt AG; Alter G; Le Gars M; Sadoff J; Barouch DH
    JAMA Netw Open; 2022 Aug; 5(8):e2226335. PubMed ID: 35947380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response.
    Reimann P; Ulmer H; Mutschlechner B; Benda M; Severgnini L; Volgger A; Lang T; Atzl M; Huynh M; Gasser K; Grabher C; Mink S; Fraunberger P; Petrausch U; Hartmann B; Winder T
    Br J Haematol; 2022 Feb; 196(3):577-584. PubMed ID: 34872162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers.
    Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Schmitz KS; Geers D; Bogers S; van Haren E; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Akkerman R; Beukema M; Lafeber M; van Baarle D; de Vries RD; van der Kuy PHM; GeurtsvanKessel CH;
    Clin Infect Dis; 2023 Feb; 76(3):e533-e536. PubMed ID: 35723273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines.
    Zhang B; Huo J; Huang Y; Teo SY; Duan K; Li Y; Toh LK; Lam KP; Xu S
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
    Lyke KE; Atmar RL; Dominguez Islas C; Posavad CM; Deming ME; Branche AR; Johnston C; El Sahly HM; Edupuganti S; Mulligan MJ; Jackson LA; Rupp RE; Rostad CA; Coler RN; Bäcker M; Kottkamp AC; Babu TM; Dobrzynski D; Martin JM; Brady RC; Frenck RW; Rajakumar K; Kotloff K; Rouphael N; Szydlo D; PaulChoudhury R; Archer JI; Crandon S; Ingersoll B; Eaton A; Brown ER; McElrath MJ; Neuzil KM; Stephens DS; Post DJ; Lin BC; Serebryannyy L; Beigel JH; Montefiori DC; Roberts PC;
    NPJ Vaccines; 2023 Jul; 8(1):98. PubMed ID: 37433788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines.
    Hvidt AK; Baerends EAM; Søgaard OS; Stærke NB; Raben D; Reekie J; Nielsen H; Johansen IS; Wiese L; Benfield TL; Iversen KK; Mustafa AB; Juhl MR; Petersen KT; Ostrowski SR; Lindvig SO; Rasmussen LD; Schleimann MH; Andersen SD; Juhl AK; Dietz LL; Andreasen SR; Lundgren J; Østergaard L; Tolstrup M;
    Front Med (Lausanne); 2022; 9():994160. PubMed ID: 36262278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S.
    Jacob-Dolan C; Lifton M; Powers OC; Miller J; Hachmann NP; Vu M; Surve N; Mazurek CR; Fisher JL; Rodrigues S; Patio RC; Anand T; Le Gars M; Sadoff J; Schmidt AG; Barouch DH
    iScience; 2024 May; 27(5):109716. PubMed ID: 38655202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S.
    Barbeau DJ; Martin JM; Carney E; Dougherty E; Doyle JD; Dermody TS; Hoberman A; Williams JV; Michaels MG; Alcorn JF; Paul Duprex W; McElroy AK
    NPJ Vaccines; 2022 Jul; 7(1):77. PubMed ID: 35794181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Study of T-Cell Repertoires after COVID-19 Immunization with Homologous or Heterologous Vaccine Booster.
    Tatsi EB; Filippatos F; Bello T; Syriopoulou V; Michos A
    Pathogens; 2024 Mar; 13(4):. PubMed ID: 38668239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.